Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $16.91M rose 36.2% year over year, behind the +55.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 8.4% from the prior quarter. Over 3 fiscal years it compounded at +58.0% a year.
Context
- Selling, general & admin amounted to 533.2% of revenue in FY2025, down 61.8 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $64.33M (+20.6%) for the fiscal year ending Dec 2026, a slowdown from the +79.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $16.91M+8.4% QoQ
- Last fiscal yearDec 2025
- $53.32M+79.2% YoY
- LTMMar 2026
- $57.81M+55.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 53.32M USD
- Year-over-year change
- +79.2%
- 3-year CAGR
- +58.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.32M | +79.2% |
| FY2024 | 2024-12-31 | 29.75M | +73.8% |
| FY2023 | 2023-12-31 | 17.11M | +26.7% |
| FY2022 | 2022-12-31 | 13.51M | — |
Selling, General & Admin vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's LTM Mar 2026 selling, general & admin of $57.81M is the 2nd highest of the 8 companies compared; the peer median is $27.71M.
- Its year-over-year change of +55.3% is the highest of 8, against a peer median of +4.7%.
- Over three fiscal years its annual growth of +58.0% compares with a peer median of +18.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $69.54M | -16.7% | +16.7% | 980.1% | |
| LTM Mar 2026 | $57.81M | +55.3% | +58.0% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $39.39M | +37.0% | — | — |
| LTM Mar 2026 | $32.75M | -0.8% | +0.8% | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $27.71M | +38.6% | +59.9% | 834.2% |
| LTM Mar 2026 | $22.58M | +5.5% | -4.4% | 269.8% | |
| LTM Mar 2026 | $17.08M | -4.8% | +20.7% | 31.8% | |
| FY2025 | $10.77M | +4.7% | +31.3% | — | |
| Peer median (excluding ZBIO) | $27.71M | +4.7% | +18.7% | 552.0% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 50M | 5M | 10M |
| Cost of Revenue | 61.69M | 0 | 139.14M | 0 |
| Gross Profit | (61.69M) | 50M | (134.14M) | 10M |
| Gross Margin | — | 100.0% | -2682.8% | 100.0% |
| Research & Development | 62.69M | 60.03M | 139.14M | 168.06M |
| Selling, General & Admin | 13.51M | 17.11M | 29.75M | 53.32M |
| Operating Expenses | 14.51M | 87.15M | 29.75M | 221.39M |
| Depreciation & Amortization | 78K | 113K | 137K | 56K |
| EBITDA | (75.12M) | (27.03M) | (156.42M) | (370.43M) |
| EBITDA Margin | — | -54.1% | -3128.4% | -3704.3% |
| Operating Income | (76.2M) | (37.15M) | (163.89M) | (211.39M) |
| Operating Margin | — | -74.3% | -3277.8% | -2113.8% |
| Interest Income | 0 | 0 | 0 | 12.15M |
| Interest Expense | 0 | 0 | 0 | 7.33M |
| Other Income / Expenses | (43.08M) | 324K | 7.33M | (166.43M) |
| Income Before Tax | (119.28M) | (36.82M) | (156.56M) | (377.82M) |
| Pre-Tax Margin | — | -73.6% | -3131.2% | -3778.2% |
| Income Tax Expense | 0 | 301K | 429K | (79K) |
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Net Margin | — | -74.2% | -3139.8% | -3777.4% |
| EPS (Basic) | (3.11) | (0.97) | (3.76) | (8.44) |
| EPS (Diluted) | (3.11) | (0.97) | (3.76) | (8.44) |
| Weighted Avg Shares | 38.32M | 38.32M | 41.79M | 44.73M |
| Weighted Avg Shares (Diluted) | 38.32M | 38.32M | 41.79M | 44.73M |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.